Some exciting news for our Canadian users of Continuous Glucose Monitoring (CGM) technology – The Dexcom G7 sensor has officially appeared on Health Canada’s list of approved devices! While this is a significant milestone, it is important to note that this approval does not provide a timeline for when the product will be available for sale in Canada. Nevertheless, this is an exciting and very important step towards getting Dexcom G7 into the hands (and arms!) of Canadians.
Dexcom’s G7, the latest in its line of innovative CGM technology, has been making waves in the international diabetes care community. The product was initially launched in countries like the United Kingdom, Ireland, Germany, Austria, and Hong Kong, and in December of last year, the US finally announced its launch. The appearance of the G7 on Health Canada’s approved devices list signals that Canadian users may soon have access to this game-changing technology.
While this is a significant step, it comes without an official announcement from Dexcom about when sales of the G7 will begin in Canada. We are eagerly awaiting that soon! The approval from Health Canada signifies that the G7 meets the necessary safety and effectiveness standards for medical devices, but the timeline for sales is yet to be confirmed.
The Dexcom G7 brings several exciting features to the table:
- It’s impressively compact, roughly the size of a nickel, and thinner than its predecessor.
- The device also warms up in just 30 minutes, four times faster than the Dexcom G6.
- Additionally, users will appreciate the 12-hour grace period for replacing finished sensors, making the transition between sessions smoother.
- The G7 boasts a streamlined mobile app with Dexcom Clarity integration, which aids users and their healthcare teams in monitoring health data.
- Future software updates promise a direct interface with the Apple Watch, further enhancing user convenience.
- The G7’s improved sensor application process and eco-friendly reduced packaging are other noteworthy features.
The Health Canada approval of the G7 is a positive development in Dexcom’s mission to bring its revolutionary technology to as many people as possible.
Stay with us for more updates as we continue to monitor this situation closely. We’ll let you know as soon as we hear any official word from Dexcom regarding the G7’s sales timeline in Canada. Until then, we celebrate this approval as a hopeful step forward in diabetes care for Canadians.
